BR0109671A - Método para a produção de um efeito de danificação vascular em um animal de sangue quente, medicamento, kit, e, usos de um agente de danificação vascular e zd6126 ou de seus sais farmaceuticamente aceitável - Google Patents
Método para a produção de um efeito de danificação vascular em um animal de sangue quente, medicamento, kit, e, usos de um agente de danificação vascular e zd6126 ou de seus sais farmaceuticamente aceitávelInfo
- Publication number
- BR0109671A BR0109671A BR0109671-0A BR0109671A BR0109671A BR 0109671 A BR0109671 A BR 0109671A BR 0109671 A BR0109671 A BR 0109671A BR 0109671 A BR0109671 A BR 0109671A
- Authority
- BR
- Brazil
- Prior art keywords
- vascular damaging
- pharmaceutically acceptable
- medicament
- warm
- kit
- Prior art date
Links
- 230000000254 damaging effect Effects 0.000 title abstract 8
- 230000002792 vascular Effects 0.000 title abstract 8
- 239000003795 chemical substances by application Substances 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
"MéTODO PARA A PRODUçãO DE UM EFEITO DE DANIFICAçãO VASCULAR EM UM ANIMAL DE SANGUE QUENTE, MEDICAMENTO, KIT, E, USOS DE UM AGENTE DE DANIFICAçãO VASCULAR E DE ZD6126 OU DE SEUS SAIS FARMACEUTICAMENTE ACEITáVEL". A invenção diz respeito ao uso de um agente de danificação vascular ou um seu sal farmaceuticamente aceitável, na fabricação de um medicamento para administração em doses divididas para uso na produção de um efeito de danificação vascular em um animal de sangue quente, tal como um ser humano. Em particular, o agente de danificação vascular é ZD6126, ou um sal deste farmaceuticamente aceitável. A invenção também diz respeito a métodos de tratamento usando um agente de danificação vascular em doses divididas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0007740A GB0007740D0 (en) | 2000-03-31 | 2000-03-31 | Combination therapy |
GB0013928A GB0013928D0 (en) | 2000-06-08 | 2000-06-08 | Methods of treatment |
GB0014904A GB0014904D0 (en) | 2000-06-20 | 2000-06-20 | Methods of treatment |
PCT/GB2001/001329 WO2001074369A1 (en) | 2000-03-31 | 2001-03-27 | Divided dose therapies with vascular damaging activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0109671A true BR0109671A (pt) | 2003-02-04 |
Family
ID=27255635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0109671-0A BR0109671A (pt) | 2000-03-31 | 2001-03-27 | Método para a produção de um efeito de danificação vascular em um animal de sangue quente, medicamento, kit, e, usos de um agente de danificação vascular e zd6126 ou de seus sais farmaceuticamente aceitável |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030055024A1 (pt) |
EP (1) | EP1272200B1 (pt) |
JP (1) | JP2003528921A (pt) |
KR (1) | KR20020084267A (pt) |
CN (1) | CN1422157A (pt) |
AT (1) | ATE298240T1 (pt) |
AU (2) | AU4258601A (pt) |
BR (1) | BR0109671A (pt) |
CA (1) | CA2402078A1 (pt) |
CZ (1) | CZ20023231A3 (pt) |
DE (1) | DE60111622T2 (pt) |
EE (1) | EE200200549A (pt) |
ES (1) | ES2243466T3 (pt) |
HU (1) | HUP0300576A3 (pt) |
IL (1) | IL151627A0 (pt) |
IS (1) | IS6555A (pt) |
MX (1) | MXPA02009603A (pt) |
NO (1) | NO20024683L (pt) |
NZ (1) | NZ534190A (pt) |
PL (1) | PL357282A1 (pt) |
PT (1) | PT1272200E (pt) |
SK (1) | SK13902002A3 (pt) |
WO (1) | WO2001074369A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
FR2848212B1 (fr) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation |
EP1658084A2 (en) * | 2003-06-18 | 2006-05-24 | Angiogene Pharmaceuticals Ltd | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO86439B (ro) * | 1982-01-15 | 1985-03-31 | Eli Lilly And Company | Procedeu pentru prepararea unor derivati de acid ascorbic |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
AU6605690A (en) * | 1989-10-27 | 1991-05-31 | Du Pont Merck Pharmaceutical Company, The | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
ES2064101T3 (es) * | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
US6194439B1 (en) * | 1991-05-29 | 2001-02-27 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
JPH11228594A (ja) * | 1998-02-16 | 1999-08-24 | Meiji Milk Prod Co Ltd | 新規プロゲステロン化合物 |
ES2265948T3 (es) * | 1999-06-14 | 2007-03-01 | Cancer Research Technology Limited | Terapia para el cancer. |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
-
2001
- 2001-03-27 CZ CZ20023231A patent/CZ20023231A3/cs unknown
- 2001-03-27 AT AT01915495T patent/ATE298240T1/de not_active IP Right Cessation
- 2001-03-27 IL IL15162701A patent/IL151627A0/xx unknown
- 2001-03-27 HU HU0300576A patent/HUP0300576A3/hu unknown
- 2001-03-27 AU AU4258601A patent/AU4258601A/xx active Pending
- 2001-03-27 EE EEP200200549A patent/EE200200549A/xx unknown
- 2001-03-27 ES ES01915495T patent/ES2243466T3/es not_active Expired - Lifetime
- 2001-03-27 AU AU2001242586A patent/AU2001242586B2/en not_active Ceased
- 2001-03-27 PL PL01357282A patent/PL357282A1/xx not_active Application Discontinuation
- 2001-03-27 CA CA002402078A patent/CA2402078A1/en not_active Abandoned
- 2001-03-27 KR KR1020027012915A patent/KR20020084267A/ko not_active Application Discontinuation
- 2001-03-27 JP JP2001572112A patent/JP2003528921A/ja active Pending
- 2001-03-27 DE DE60111622T patent/DE60111622T2/de not_active Expired - Fee Related
- 2001-03-27 NZ NZ534190A patent/NZ534190A/en unknown
- 2001-03-27 SK SK1390-2002A patent/SK13902002A3/sk unknown
- 2001-03-27 PT PT01915495T patent/PT1272200E/pt unknown
- 2001-03-27 US US10/239,898 patent/US20030055024A1/en not_active Abandoned
- 2001-03-27 CN CN01807663A patent/CN1422157A/zh active Pending
- 2001-03-27 BR BR0109671-0A patent/BR0109671A/pt not_active IP Right Cessation
- 2001-03-27 EP EP01915495A patent/EP1272200B1/en not_active Expired - Lifetime
- 2001-03-27 WO PCT/GB2001/001329 patent/WO2001074369A1/en not_active Application Discontinuation
- 2001-03-27 MX MXPA02009603A patent/MXPA02009603A/es unknown
-
2002
- 2002-09-19 IS IS6555A patent/IS6555A/is unknown
- 2002-09-30 NO NO20024683A patent/NO20024683L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2402078A1 (en) | 2001-10-11 |
AU2001242586B2 (en) | 2004-12-16 |
WO2001074369A1 (en) | 2001-10-11 |
PT1272200E (pt) | 2005-09-30 |
SK13902002A3 (sk) | 2003-05-02 |
NO20024683D0 (no) | 2002-09-30 |
ES2243466T3 (es) | 2005-12-01 |
NZ534190A (en) | 2007-05-31 |
AU4258601A (en) | 2001-10-15 |
DE60111622T2 (de) | 2006-05-18 |
US20030055024A1 (en) | 2003-03-20 |
EE200200549A (et) | 2004-02-16 |
IS6555A (is) | 2002-10-18 |
IL151627A0 (en) | 2003-04-10 |
PL357282A1 (en) | 2004-07-26 |
CZ20023231A3 (cs) | 2003-01-15 |
JP2003528921A (ja) | 2003-09-30 |
CN1422157A (zh) | 2003-06-04 |
DE60111622D1 (de) | 2005-07-28 |
MXPA02009603A (es) | 2004-05-14 |
ATE298240T1 (de) | 2005-07-15 |
EP1272200B1 (en) | 2005-06-22 |
HUP0300576A2 (hu) | 2003-07-28 |
EP1272200A1 (en) | 2003-01-08 |
HUP0300576A3 (en) | 2005-02-28 |
NO20024683L (no) | 2002-10-15 |
KR20020084267A (ko) | 2002-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412426A (pt) | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente | |
PT97552A (pt) | Processo para a preparacao de formas de dosagem para administracao de farmacos para o tratamento da doenca de parkison | |
BR0313116A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável. | |
DK0796103T3 (da) | Anvendelse af røgelse til behandling af Alzheimer-sygdommen | |
BR0109671A (pt) | Método para a produção de um efeito de danificação vascular em um animal de sangue quente, medicamento, kit, e, usos de um agente de danificação vascular e zd6126 ou de seus sais farmaceuticamente aceitável | |
US5945119A (en) | Therapeutic preparations containing caesium ions | |
US6011061A (en) | Therapeutic methods and preparations using rubidium ions | |
IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
JP2001316293A5 (pt) | ||
EDELSON et al. | Evaluation of a new drug for topical therapy of tinea capitis | |
RU2286791C1 (ru) | Способ лечения рубцов | |
SE9101341D0 (sv) | New medicinal use | |
Tromovitch et al. | Failure of chemical epilation in the treatment of tinea capitis | |
Belisario | Mycotic infections and their treatment | |
RU94000695A (ru) | Средство с противоаллергическим действием | |
RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
BR0316192A (pt) | Método e composições para o tratamento da ansiedade | |
ATE464051T1 (de) | Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz | |
Johnston | Intravenous procaine in the treatment of the arthritides | |
Chand | Verrucae (warts) | |
RUSSELL et al. | injection. | |
Hanke et al. | Basal cell nevus syndrome responses | |
Mac READY | Botox Can Soften Defects in Lower Face | |
WICK | SALICYLATE OF AMMONIUM FOR FEVERS. | |
EA006527B1 (ru) | Способ подготовки к оказанию скорой медицинской помощи в экстремальных условиях |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009. |